跳轉至內容
Merck
  • Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.

Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.

Bioorganic & medicinal chemistry letters (2005-06-01)
Zsolt Székelyhidi, János Pató, Frigyes Wáczek, Péter Bánhegyi, Bálint Hegymegi-Barakonyi, Dániel Erös, György Mészáros, Ferenc Hollósy, Doris Hafenbradl, Sabine Obert, Bert Klebl, György Kéri, László Orfi
摘要

SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined LogP and LogS values.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
秋水仙碱, ≥95% (HPLC), powder
Sigma-Aldrich
茶碱, anhydrous, ≥99%, powder
Sigma-Aldrich
吲哚, ≥99%
Sigma-Aldrich
苯戊酮, 99%
Sigma-Aldrich
秋水仙碱, BioReagent, suitable for plant cell culture, ≥95% (HPLC)
Sigma-Aldrich
苯并咪唑, 98%
Sigma-Aldrich
苯乙酮, ReagentPlus®, 99%
Sigma-Aldrich
苯乙酮, ≥98%, FG
Sigma-Aldrich
丁酰苯, ≥99%
Sigma-Aldrich
吲哚, ≥99%, FG
Supelco
苯乙酮, analytical standard
Supelco
吲哚, analytical standard
Sigma-Aldrich
苯乙酮, puriss. p.a., ≥99.0% (GC)